These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

624 related items for PubMed ID: 27835874

  • 1. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R, Alì G, Giannini R, Proietti A, Lucchi M, Chella A, Melfi F, Mussi A, Fontanini G.
    Oncotarget; 2017 Jan 10; 8(2):2758-2770. PubMed ID: 27835874
    [Abstract] [Full Text] [Related]

  • 2. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
    Alì G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, Boldrini L, Lucchi M, Mussi A, Fontanini G.
    J Thorac Oncol; 2013 Nov 10; 8(11):1389-95. PubMed ID: 24084442
    [Abstract] [Full Text] [Related]

  • 3. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
    Hida T, Matsumoto S, Hamasaki M, Kawahara K, Tsujimura T, Hiroshima K, Kamei T, Taguchi K, Iwasaki A, Oda Y, Honda H, Nabeshima K.
    Cancer Sci; 2015 Nov 10; 106(11):1635-41. PubMed ID: 26291840
    [Abstract] [Full Text] [Related]

  • 4. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, Galateau-Sallé F, Copin MC, Hofman P, Cazes A, Andujar P, Imbeaud S, Petel F, Pairon JC, Le Pimpec-Barthes F, Zucman-Rossi J, Jean D.
    Clin Cancer Res; 2014 Mar 01; 20(5):1323-34. PubMed ID: 24443521
    [Abstract] [Full Text] [Related]

  • 5. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
    Ramírez-Salazar EG, Salinas-Silva LC, Vázquez-Manríquez ME, Gayosso-Gómez LV, Negrete-Garcia MC, Ramírez-Rodriguez SL, Chávez R, Zenteno E, Santillán P, Kelly-García J, Ortiz-Quintero B.
    Exp Mol Pathol; 2014 Dec 01; 97(3):375-85. PubMed ID: 25236577
    [Abstract] [Full Text] [Related]

  • 6. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M, Kinoshita Y, Hamasaki M, Matsumoto S, Hida T, Oda Y, Iwasaki A, Nabeshima K.
    Lung Cancer; 2019 Apr 01; 130():187-193. PubMed ID: 30885343
    [Abstract] [Full Text] [Related]

  • 7. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY, Wright CM, Kirschner MB, Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, van Zandwijk N, Lin RC, Reid G.
    Mol Cancer; 2016 Jun 01; 15(1):44. PubMed ID: 27245839
    [Abstract] [Full Text] [Related]

  • 8. Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology: A Gene Expression Panel versus BRCA1-Associated Protein 1 and p16 Tests.
    Bruno R, Alì G, Poma AM, Proietti A, Libener R, Mariani N, Niccoli C, Chella A, Ribechini A, Grosso F, Fontanini G.
    J Mol Diagn; 2020 Apr 01; 22(4):457-466. PubMed ID: 32036091
    [Abstract] [Full Text] [Related]

  • 9. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
    Muraoka T, Soh J, Toyooka S, Aoe K, Fujimoto N, Hashida S, Maki Y, Tanaka N, Shien K, Furukawa M, Yamamoto H, Asano H, Tsukuda K, Kishimoto T, Otsuki T, Miyoshi S.
    Lung Cancer; 2013 Dec 01; 82(3):485-90. PubMed ID: 24168922
    [Abstract] [Full Text] [Related]

  • 10. Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.
    De Rienzo A, Richards WG, Yeap BY, Coleman MH, Sugarbaker PE, Chirieac LR, Wang YE, Quackenbush J, Jensen RV, Bueno R.
    Clin Cancer Res; 2013 May 01; 19(9):2493-502. PubMed ID: 23493352
    [Abstract] [Full Text] [Related]

  • 11. Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
    Martínez-Rivera V, Negrete-García MC, Ávila-Moreno F, Ortiz-Quintero B.
    Int J Mol Sci; 2018 Feb 17; 19(2):. PubMed ID: 29462963
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
    Andersen M, Grauslund M, Ravn J, Sørensen JB, Andersen CB, Santoni-Rugiu E.
    J Mol Diagn; 2014 Jul 17; 16(4):418-30. PubMed ID: 24912849
    [Abstract] [Full Text] [Related]

  • 13. DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics.
    Bertero L, Righi L, Collemi G, Koelsche C, Hou Y, Stichel D, Schrimpf D, Flucke U, Petersen I, Vokuhl C, Fröhling S, Bironzo P, Scagliotti GV, Cassoni P, Papotti M, von Deimling A.
    J Mol Diagn; 2021 Jul 17; 23(7):834-846. PubMed ID: 33887463
    [Abstract] [Full Text] [Related]

  • 14. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
    Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K.
    Pathol Int; 2016 Oct 17; 66(10):563-570. PubMed ID: 27614970
    [Abstract] [Full Text] [Related]

  • 15. Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).
    Wright CM, Kirschner MB, Cheng YY, O'Byrne KJ, Gray SG, Schelch K, Hoda MA, Klebe S, McCaughan B, van Zandwijk N, Reid G.
    PLoS One; 2013 Oct 17; 8(8):e70940. PubMed ID: 23976967
    [Abstract] [Full Text] [Related]

  • 16. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.
    J Pathol; 2015 Oct 17; 237(2):203-14. PubMed ID: 26011651
    [Abstract] [Full Text] [Related]

  • 17. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.
    Fujii M, Fujimoto N, Hiraki A, Gemba K, Aoe K, Umemura S, Katayama H, Takigawa N, Kiura K, Tanimoto M, Kishimoto T.
    Cancer Sci; 2012 Mar 17; 103(3):510-4. PubMed ID: 22146010
    [Abstract] [Full Text] [Related]

  • 18. [Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis].
    Li B, Zhou CX, Pu YQ, Qiu L, Mei W, Xiong W.
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Mar 20; 41(3):168-176. PubMed ID: 37006141
    [Abstract] [Full Text] [Related]

  • 19. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
    Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, Gao W, An B, Fujii M, Murakami H, Osada H, Taniguchi T, Usami N, Kondo M, Hasegawa Y, Shimokata K, Matsuo K, Hida T, Fujimoto N, Kishimoto T, Issa JP, Sekido Y.
    Cancer Res; 2009 Dec 01; 69(23):9073-82. PubMed ID: 19887624
    [Abstract] [Full Text] [Related]

  • 20. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV.
    J Thorac Oncol; 2018 Jan 01; 13(1):124-133. PubMed ID: 29079455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.